Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 149 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Donepezil HCl Clear all
Completed Phase 3 Interventional Results available

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

NCT02006641
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, Idalopirdine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
50 Years and older
Enrollment
858 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
48
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 30, 2026, 4:48 PM EDT
Not listed Phase 2 Interventional

Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha

NCT00031018
View directory record Official record
Conditions
Memory Disorders, Alzheimer's Disease
Interventions
Aricept, IFN-alpha2A
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2008 · Synced Oct 30, 2026, 4:48 PM EDT
Completed Phase 2Phase 3 Interventional

The Combination of Donepezil and Cognitive Training for Treating Alcohol Use Disorder

NCT04318639
View directory record Official record
Conditions
Alcohol Use Disorder, Mild Cognitive Impairment
Interventions
Donepazil
Combination Product
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
21 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 30, 2026, 4:48 PM EDT
Completed Phase 4 Interventional

A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties

NCT00315367
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Donepezil HCI (drug)
Drug
Lead sponsor
Neurognostics
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 16, 2007 · Synced Oct 30, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Donepezil in Preventing Delirium in Hospitalized Elderly

NCT00182884
View directory record Official record
Conditions
Postoperative Complications, Delirium
Interventions
Donepezil
Drug
Lead sponsor
Indiana University Health
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Oct 30, 2026, 4:48 PM EDT
Terminated Phase 3 Interventional Results available

12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension

NCT02586909
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
RVT-101 35 mg tablets
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years to 86 Years
Enrollment
1,099 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Phoenix, Arizona • Tucson, Arizona • Rancho Mirage, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 30, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Results available

Detecting an Early Response to Donepezil With Measures of Visual Attention

NCT03073876
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donepezil Hydrochloride, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
50 Years to 95 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2021
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 30, 2026, 4:48 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment

NCT00688376
View directory record Official record
Conditions
Attention Impairment
Interventions
Donepezil hydrochloride, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
13
States / cities
Stanford, California • Miami, Florida • Minneapolis, Minnesota + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 30, 2026, 4:48 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Telerehabilitation Alzheimer's Disease Feasibility (TADF)

NCT04732182
View directory record Official record
Conditions
Alzheimer Disease, Healthy Aging
Interventions
BrightGo cognitive training, Standard of Care medication for early Alzheimer's Disease
Device · Drug
Lead sponsor
Bright Cloud International Corp
Industry
Eligibility
65 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
New Brunswick, New Jersey • North Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 30, 2026, 4:48 PM EDT
Terminated Phase 4 Interventional Results available

Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain

NCT01743976
View directory record Official record
Conditions
Neuropathic Pain
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 30, 2026, 4:48 PM EDT
Not listed Phase 3 Interventional

Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome

NCT00069550
View directory record Official record
Conditions
Rett Syndrome
Interventions
dextromethorphan, donepezil hydrochloride
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
1 Year to 15 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 4:48 PM EDT
Terminated Not applicable Interventional Results available

Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease

NCT01082965
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Oct 30, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Pharmacokinetics (PK) of Corplex™ Donepezil Transdermal Delivery System (TDS) Applied to Different Body Locations

NCT03432195
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Donepezil TDS
Drug
Lead sponsor
Corium, Inc.
Industry
Eligibility
30 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 30, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Results available

Neural Correlates In Mild Alzheimer's Disease

NCT00477659
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Donepezil hydrochloride
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 30, 2026, 4:48 PM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

NCT01712074
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-05212377 (SAM-760), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
40
States / cities
Costa Mesa, California • Imperial, California • Rancho Mirage, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 30, 2026, 4:48 PM EDT
Completed Phase 3 Interventional Results available

Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease

NCT00478205
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aricept (donepezil SR 23 mg), Aricept (donepezil IR 10 mg)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
1,467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Hickory, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 30, 2026, 4:48 PM EDT
Recruiting Not applicable Interventional

δ in Dementia Clinical Trials

NCT05592678
View directory record Official record
Conditions
Alzheimer's Disease (AD), Dementia, Cognitive Decline, Mild Cognitivie Impairment (MCI)
Interventions
Donepezil
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
65 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 30, 2026, 4:48 PM EDT
Withdrawn Phase 2 Interventional

CPC-201 Alzheimer's Disease Type Dementia: PET Study

NCT02860065
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CPC-201, Positron emission tomography (PET)
Drug · Other
Lead sponsor
Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Industry
Eligibility
50 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
West Bloomfield, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 30, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Donepezil on Gait and Balance in Parkinson's Disease

NCT01521117
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 30, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Results available

Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly

NCT01951118
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Delirium, Dementia, Amnestic, Cognitive Disorders
Interventions
Donepezil
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 30, 2026, 4:48 PM EDT
Completed Phase 3 Interventional Results available

Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease

NCT00428389
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rivastigmine 5 cm^2 transdermal patch, Rivastigmine 10 cm^2 transdermal patch
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
23
States / cities
Sun City, Arizona • Costa Mesa, California • Fresno, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Oct 30, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions

NCT01260948
View directory record Official record
Conditions
Healthy
Interventions
Donepezil Hydrochloride, Aricept®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
East Grand Forks, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2011 · Synced Oct 30, 2026, 4:48 PM EDT
Completed Phase 1 Interventional

Drug-Drug Interaction Study With Aricept® (Donepezil)

NCT01042314
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donepezil, BMS-708163
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Oct 30, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Results available

Study in Elderly Alzheimer's Patients to Assess Skin Tolerability, Irritation With 3, 7-Day Applications of DTP-System

NCT00916383
View directory record Official record
Conditions
Irritation/Irritant
Interventions
350 mg Donepezil Transdermal Patch, Placebo Patch
Drug
Lead sponsor
Teikoku Pharma USA, Inc.
Industry
Eligibility
65 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
7
States / cities
Phoenix, Arizona • Fresno, California • Garden Grove, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 30, 2026, 4:48 PM EDT